section name header

Pronunciation ⬇

e-FED-rin

Classifications ⬆ ⬇

Therapeutic Classification: vasopressors

Pharmacologic Classification: adrenergics

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Acts as an agonist at both alpha- and beta-receptors; also indirectly stimulates release of norepinephrine, which results in vasoconstriction and increased cardiac output.
Therapeutic effects:
  • Increased BP.

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Metabolized into norephedrine. Primarily excreted as unchanged drug and metabolite in urine.

Half-Life: 6 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
IVunknownunknownunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: bradycardia, hypertension, palpitations, tachycardia

GI: nausea, vomiting

Neuro: dizziness, restlessness

Misc: tolerance

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Akovaz, Corphedra, Emerphed, Rezipres

Code ⬆

NDC Code